Patient Guide to Support Services

Array BioPharma


Array BioPharma, via its ArrayACTS patient support program, offers several financial assistance options and support services for patients who have been prescribed the combination of Braftovi (encorafenib) and Mektovi (binimetinib) but who cannot afford to pay for them.

Braftovi and Mektovi are 2 kinase inhibitors indicated for use in combination for the treatment of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test (Table).


ArrayACTS offers a range of patient support services for patients who are prescribed Braftovi and Mektovi. These services include:

  • Financial assistance
  • Insurance benefits investigation and verification
  • Prior authorization and appeals support.

Depending on the patients’ insurance coverage, one of the following financial assistance options offered by ArrayACTS may apply.

Array Co-Pay Savings Program

The Array Co-Pay Savings Program can help patients with commercial insurance who have been prescribed Braftovi plus Mektovi in paying the out-of-pocket prescription drug costs. Eligible patients may pay as little as $0 per month, for a maximum of $25,000 annually.

Patient Assistance Program

The Patient Assistance Program provides financial assistance for uninsured or underinsured patients who cannot afford to pay for Braftovi and Mektovi.

In addition, ArrayACTS helps patients with commercial or government insurance—including Medicare, Medicare Part D, and Medicaid—find financial assistance, by providing referral to independent copay assistance foundations; eligibility is determined by the individual foundation.


Array Co-Pay Savings Program

To enroll in the Array Co-Pay Savings Program, patients must:

  • Have commercial (private or nongovernment) insurance
  • Be prescribed Braftovi capsules and Mektovi tablets for an FDA-approved indication
  • Not be participating in federal- or state-funded insurance programs, including Medicare or Medicaid
  • Not seek reimbursement from any insurance company, health plan, or third-party payer
  • Be aged ≥18 years
  • Reside in the United States or in Puerto Rico.

Patient Assistance Program

To qualify for the Patient Assistance Program for Braftovi and Mektovi, patients must:

  • Meet specified financial and eligibility requirements
  • Be uninsured or underinsured with a commercial or government insurance
  • Have already tried other types of patient assistance, including the Array Co-Pay Savings Program and any support from independent copay assistance foundations.

For more information about the Patient Assistance Program, please call ArrayACTS, at 866-277-2927.

Application & Enrollment


To enroll in ArrayACTS, the online enrollment form must be completed by the prescriber or by the specialty pharmacy and submitted online. The drug prescription, as well as documentation relating to the patient’s insurance coverage or reimbursement, must also be provided.

Array Co-Pay Savings Program

Enrollment in the Array Co-Pay Savings Program may be done by the prescriber or by the specialty pharmacy; the online application is available here.

For more information on ArrayACTS and all the available financial assistance programs, please call 866-277-2927.

Table Array BioPharma Oncology Drugs

Patient support programs

Braftovi (encorafenib) + Mektovi (binimetinib)
Treatment of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: